Cipla Gulf Signs an Exclusive Commercialization Agreement with Alvotech for AVT02 (biosimilar, adalimumab)

 Cipla Gulf Signs an Exclusive Commercialization Agreement with Alvotech for AVT02 (biosimilar, adalimumab)

Cipla Gulf Signs an Exclusive Commercialization Agreement with Alvotech for AVT02 (biosimilar, adalimumab)

Shots:

  • Alvotech will take care of development and supply of the product while Cipla Gulf, subsidiary of Cipla will be responsible for Alvotech’s AVT02 registration and commercialization
  • The agreement will allow Alvotech to have access for Cipla’s strong commercial network in selected emerging markets enabling patients with high-quality biosimilars
  • Alvotech’s AVT02 is a mAb and a biosimilar to AbbVie’s Humira involved in neutralizing TNF-α targeted for several autoimmune diseases including RA, AS, PP, Psoriatic Arthritis, UC, CD and is currently evaluated in P-III trial with its BLA submission with US FDA and EMA in H1’20

Click here to read full press release/ article | Ref: Cipla | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post